Neural Regeneration Research ›› 2023, Vol. 18 ›› Issue (9): 1884-1889.doi: 10.4103/1673-5374.367983

Previous Articles     Next Articles

Brain organoids are new tool for drug screening of neurological diseases

Jin-Qi Zhou1, 2, #, Ling-Hui Zeng1, 2, #, Chen-Tao Li1, 2, Da-Hong He1, 2, Hao-Duo Zhao1, 2, Yan-Nan Xu1, 2, Zi-Tian Jin1, 2, Chong Gao1, 2, *   

  1. 1School of Medicine, Institute of Brain and Cognitive Science, Hangzhou City University, Hangzhou, Zhejiang Province, China; 2Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang Province, China
  • Online:2023-09-15 Published:2023-03-06
  • Contact: Chong Gao, PhD, gaoc@zucc.edu.cn.
  • Supported by:
    This work was supported by the National Natural Science Foundation of China, No. 32000498; the Startup Funding of Zhejiang University City College, No. 210000-581849 (both to CG); and National College Students’ Innovative Entrepreneurial Training Plan Program, No. 202113021024 (to JQZ). 

PDF

290

Abstract: At the level of in vitro drug screening, the development of a phenotypic analysis system with high-content screening at the core provides a strong platform to support high-throughput drug screening. There are few systematic reports on brain organoids, as a new three-dimensional in vitro model, in terms of model stability, key phenotypic fingerprint, and drug screening schemes, and particularly regarding the development of screening strategies for massive numbers of traditional Chinese medicine monomers. This paper reviews the development of brain organoids and the advantages of brain organoids over induced neurons or cells in simulated diseases. The paper also highlights the prospects from model stability, induction criteria of brain organoids, and the screening schemes of brain organoids based on the characteristics of brain organoids and the application and development of a high-content screening system. 

Key words: brain organoids, disease modeling, high-content system, multiple omic analysis, network pharmacology, neurodegeneration, phenotypic fingerprint, psychiatric diseases, stem cells, traditional Chinese medicine drug screening